Last reviewed · How we verify
TD1414 2% cream
TD1414 2% cream is a Small molecule drug developed by LEO Pharma. It is currently in Phase 2 development.
At a glance
| Generic name | TD1414 2% cream |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo (PHASE2)
- Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TD1414 2% cream CI brief — competitive landscape report
- TD1414 2% cream updates RSS · CI watch RSS
- LEO Pharma portfolio CI
Frequently asked questions about TD1414 2% cream
What is TD1414 2% cream?
TD1414 2% cream is a Small molecule drug developed by LEO Pharma.
Who makes TD1414 2% cream?
TD1414 2% cream is developed by LEO Pharma (see full LEO Pharma pipeline at /company/leo-pharma).
What development phase is TD1414 2% cream in?
TD1414 2% cream is in Phase 2.
Related
- Manufacturer: LEO Pharma — full pipeline
- Compare: TD1414 2% cream vs similar drugs
- Pricing: TD1414 2% cream cost, discount & access